To the full analysis
Buyback calculator for SELLAS Life Sciences Group
SELLAS Life Sciences Group stock: key metrics
SLSSELLAS Life Sciences Group had an operating margin of 0% and a return on invested capital (ROIC) of −54.6% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | no data | no data | no data |
| 2007 | no data | no data | no data |
| 2008 | no data | no data | no data |
| 2009 | no data | no data | no data |
| 2010 | no data | no data | no data |
| 2011 | no data | no data | no data |
| 2012 | −2.4% | −1,040.2% | −1,715.8% |
| 2013 | 79.1% | −1,360.7% | −3,083.2% |
| 2014 | 84.9% | −392.8% | −392.8% |
| 2015 | no data | no data | no data |
| 2016 | no data | no data | no data |
| 2017 | no data | no data | no data |
| 2018 | no data | no data | no data |
| 2019 | no data | no data | no data |
| 2020 | 100.0% | −893.8% | −881.9% |
| 2021 | 97.4% | −332.8% | −272.4% |
| 2022 | 90.0% | −4,195.0% | −4,130.1% |
| 2023 | no data | no data | no data |
| 2024 | no data | no data | no data |
| 2025 | no data | no data | no data |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | −100.0% | no data | −100.0% |
| 2007 | −100.0% | no data | −90.5% |
| 2008 | −100.0% | no data | −100.0% |
| 2009 | −100.0% | no data | −100.0% |
| 2010 | −100.0% | no data | −100.0% |
| 2011 | −100.0% | no data | −37.1% |
| 2012 | −100.0% | −56.5% | −63.6% |
| 2013 | −100.0% | −80.1% | −87.2% |
| 2014 | −98.8% | −68.2% | −45.5% |
| 2015 | no data | −62.2% | no data |
| 2016 | −82.2% | −37.7% | −35.8% |
| 2017 | −100.0% | −65.8% | −70.9% |
| 2018 | −100.0% | no data | −100.0% |
| 2019 | −100.0% | no data | −100.0% |
| 2020 | −59.9% | −59.6% | −36.4% |
| 2021 | −100.0% | −72.2% | −78.3% |
| 2022 | −100.0% | no data | −100.0% |
| 2023 | 200.0% | no data | −100.0% |
| 2024 | −100.0% | no data | −100.0% |
| 2025 | −37.9% | −54.6% | −34.3% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Mar 2009)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.